• 1
    Morris P, Hopwood M, Maguire K et al. Blunted prolactin response to d-fenfluramine in post-stroke major depression. J. Affect Disord 2003; 76: 273278.
  • 2
    Glodzik-Sobanska L, Slowik A, McHugh P et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Res. 2006; 148: 111120.
  • 3
    Tang WK, Chan SS, Chiu HF et al. Can the Geriatric Depression Scale detect post-stroke depression in Chinese elderly? J. Affect Disord 2004; 81: 153156.
  • 4
    Rampello L, Alvano A, Chiechio S et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by ‘retarded’ post-stroke depression: A random, placebo-controlled study. Arch. Gerontol. Geriatr. 2005; 40: 275285.
  • 5
    Toso V, Gandolfo C, Paolucci S et al. Post-stroke depression: Research methodology of a large multicenter observational study (DESTRO). Neurol. Sci. 2004; 25: 138144.
  • 6
    Bhatia MS. Post-stroke depression and cerebral laterality. Eur. Psychiatry 2004; 19: 454458.
  • 7
    Aben I, Verhey F, Honig A et al. Research into the specificity of depression after stroke: A review on an unresolved issue. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 25: 671689.
  • 8
    Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol. Bull. 2002; 36: 623.
  • 9
    Wirz-Justice A, Terman M, Oren DA et al. Brightening depression. Science 2004; 303: 467469.
  • 10
    Wu H, Guan C, Qin X et al. Upregulation of substance P receptor expression by calcitonin gene-related peptide, a possible cooperative action of two neuropeptides involved in airway inflammation. Pulm. Pharmacol. Ther. 2007; 20: 13524.
  • 11
    Yamaoka J, Kawana S. Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J. Dermatol. Sci. 2007; 8: 123132.
  • 12
    Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 16401645.
  • 13
    Ma QP, Bleasdale C. Modulation of brain stem monoamines and gamma-aminobutyric acid by NK1 receptors in rats. Neuroreport 2002; 13: 18091812.
  • 14
    Froger N, Gardier AM, Moratalla R et al. 5-hydroxytryptamine (5-HT)1Aautoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 2001; 21: 81888197.
  • 15
    Stoessl AJ, Dourish CT, Young SC et al. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neurosci. Lett. 1987; 80: 321326.
  • 16
    Stoessl AJ, Dourish CT, Iversen SD. Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: Evidence for mediation by endogenous 5-HT. Brain Res. 1990; 517: 111116.
  • 17
    Harrison S, Geppetti P. Substance P. Int. J. Biochem. Cell Biol. 2001; 33: 555576.
  • 18
    Deuschle M, Sander P, Herpfer I et al. Substance P in serum and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment. Psychiatry Res. 2005; 136: 16.
  • 19
    Blier P, Gobbi G, Haddjeri N et al. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/anxiolytic response. J. Psychiatr. Neurosci. 2004; 29: 208218.
  • 20
    Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiatry 2002; 63: 2529.
  • 21
    Haneda E, Higuchi M, Maeda J et al. In vivo mapping of substance P receptors in brains of laboratory animals by high-resolution imaging systems. Synapse 2007; 61: 205215.
  • 22
    Chen YF. Chinese Classification of Mental Disorders (CCMD-3): Towards integration in international classification. Psychopathology 2002; 35: 171175.
  • 23
    Beck AT, Epstein N, Brown G et al. An inventory for measuring clinical anxiety: Psychometric properties. J. Consult Clin. Psychol 1988; 56: 893897.
  • 24
    Lambiase A, Bonini S, Micera A et al. Increased plasma levels of substance P in vernal keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 1997; 38: 21612164.
  • 25
    O'Connell R, Skrabanek P, Cannon D et al. High-sensitivity radioimmunoassay for substance P. Ir. J. Med. Sci. 1976; 145: 392398.
  • 26
    Cannon D, Skrabanek P, Powell D et al. Immunological characterization of two substance-P antisera with substance-P fragments and analogues. Biochem. Soc. Trans. 1977; 5: 17361738.
  • 27
    Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry 2002; 63: 1824.
  • 28
    Kulkantrakorn K, Jirapramukpitak T. A prospective study in one year cumulative incidence of depression after ischemic stroke and Parkinson's disease: A preliminary study. J. Neurol. Sci. 2007; 263: 165168.
  • 29
    Mello DM, Marcinichen DR, Madruga D et al. Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P. Behav. Brain Res. 2007; 181: 232238.
  • 30
    Sapna S, Shivakumar K. Substance P enhances soluble ICAM-1 release from adult rat cardiac fibroblasts by a p42/44 MAPK- and PKC-mediated mechanism. Cell Biol. Int. 2007; 31: 856859.
  • 31
    Geracioti TD Jr, Carpenter LL, Owens MJ et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry 2006; 163: 637643.
  • 32
    Barker-Collo SL. Depression and anxiety 3 months post stroke: Prevalence and correlates. Arch. Clin. Neuropsychol. 2007; 22: 519531.
  • 33
    Chemerisnske E, Levine SR. Neuropsychiatric disorders following vascular brain injury. Mt. Sinai J. Med. 2006; 731006731014.
  • 34
    Norman TR, Burrows GD. Emerging treatments for major depression. Expert. Rev. Neurother. 2007; 7: 203213.